CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)
(the "**Company**")

PROPOSED ISSUANCE OF UP TO 630,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT AN ISSUE PRICE OF S$0.002 PER SHARE

- RECEIPT OF LISTING AND QUOTATION NOTICE

The board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") refers to the announcement of the Company dated 3 November 2026 (the "**Announcement**") in relation to, amongst others, the proposed issue of Consideration Shares pursuant to the Proposed Acquisition. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meaning ascribed to them in the Announcement.

The Board is pleased to update that the Company has received the listing and quotation notice from the SGX-ST granting its in-principle approval for the dealing in, listing of and quotation for 630,000,000 Consideration Shares on the Catalist Board of the SGX-ST (the "**LQN**"). The LQN is subject to the Company's compliance with the SGX-ST's listing requirements, including specific shareholders' approval being obtained at a general meeting ("**EGM**") pursuant to Listing Rule 805. The LQN is not to be taken as an indication of merits of the Company, its subsidiaries, its securities (including the Consideration Shares), or any related transaction contemplated by the LQN.

The Company will be convening an EGM to obtain shareholders' approval for the proposed issue of the Consideration shares, the notice of which will be despatched to shareholders and announced on SGXNET in due course.

BY ORDER OF THE BOARD

Ong Choon Yi (Wang Junyi)
Executive Director and Group Chief Executive Officer
20 November 2026

---

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.*